Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 10/20 | 0.40 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21834929 | 1.00 | PTGS2 (0.41) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL6264514 | 0.83 | MAOB (0.40) | MAOBHTR2AHTR2CHTR2BLMNA | |
| SCHEMBL9541908 | 0.78 | MAOB (0.58) | MAOBHTR2AHTR2CHTR2BMAOA | |
| SCHEMBL9950472 | 0.75 | OPRK1 (0.55) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL11086077 | 0.75 | OPRK1 (0.55) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL6445552 | 0.75 | MAOB (0.65) | MAOBHTR2AHTR2CHTR2BMAOA | |
| SCHEMBL2119239 | 0.75 | OPRK1 (0.55) | PTGS2MAOBHTR2AHTR2CHTR2B | |
| SCHEMBL22504105 | 0.75 | SLC6A2 (0.41) | MAOBHTR2AHTR2CHTR2BLMNA | |
| SCHEMBL10468078 | 0.75 | LMNA (0.41) | MAOBHTR2CLMNAALDH1A1 | |
| SCHEMBL10468077 | 0.75 | LMNA (0.41) | MAOBHTR2CLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3858816-A1 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | Celltrion, Inc. (KR) | 2021-08-04 | — | — | EP | disclosed |
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | PTGS2 4151/4885MAOB 166/4885HTR2A 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.